250 results on '"di Grazia, C."'
Search Results
102. PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS IN 489 HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: AETIOLOGY, RISK FACTORS AND IMPACT ON MORTALITY
103. Graft-versus-host disease prophylaxis with antithymocyte globulin: Which is more important, dose or timing?
104. A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation
105. PRE-TRANSPLANT POSITRON EMISSION TOMOGRAPHY (PET) PREDICTS RELAPSE RATE IN PATIENTS WITH HODGKIN LYMPHOMA UNDERGOING HAPLO TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
106. Extracorporeal photopheresis for steroid refractory acute GvHD in children and adults
107. IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE
108. Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplant based on molecular monitoring is predictive of lymphoproliferative disease
109. Leukemia Relapse after Allogeneic Transplants in AML: Predictive Role of WT1 Expression and Protective Effect of DLI
110. Early detection of Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplant and pre-emptive therapy with four courses of i.v. cydofovir
111. The role of pre-transplant positron emission tomography (PET), in patients with Hodgkin disease undergoing a haplo transplants with post-transplant cyclophosphamide
112. Allogeneic hemopoletic stem cell transplantation for acute myeloid leukemia in first complete remission - Low transplant mortality despite increasing age
113. BUSULFAN FLUDARABINE (BU-FLU) COMPARED TO THIOTEPA BUSULFAN FLUDARABINE (TBF) FOR ALLOGENEIC TRANSPLANTS IN ACUTE MYELOID LEUKEMIA (AML) IN REMISSION
114. Liver resection for hemoperitoneum caused by spontaneous rupture of unrecognized hepatocellular carcinoma
115. ACUTE GRAFT VERSUS HOST DISEASE: REDUCED INCIDENCE AND PREDICTIVE FACTORS
116. Cytomegalovirus (CMV) viral load and outcome after allogeneic transplants: the effect of donor type
117. Thiotepa based conditioning regimens for allogeneic stem cell transplants: Outcome in 374 patients -with a median age of 48 - Grafted from related or unrelated donors
118. Pre-emptive treatment of acute graft versus host disease in alternative donor transplants: A randomized trial of day+7 rabbit anti-thymocyte globulin (ATG)
119. DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT) : A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS, 1 YEAR POST TRANSPLANT
120. Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative donor: incidence, risk factors and outcome
121. Acute graft-versus-host disease II-IV in 1465 patients: has outcome improved over the past two decades?
122. Bone marrow transplantation (BMT) for acquired severe aplastic anemia
123. Immune reconstitution after cord blood transplantation by direct intrabone injection of cells
124. OPTIMIZATION OF MINIMAL RESIDUAL DISEASE EVALUATION IN ACUTE MYELOID LEUKEMIA TO DRIVE POST REMISSION THERAPY
125. HIGH PREDICTIVE VALUE OF COMBINED WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA
126. Identifying patients at risk of transplant mortality on day +100 after an allogeneic HSCT: platelet counts, gamma glutamyltransferase and cholinesterase
127. Extracorporeal photopheresis for the treatment of steroid refractory acute GvHD
128. ALLOGENEIC TRANSPLANTS FOR MYELODISPLASTIC SYNDROMES: STRONG REDUCTION OF TRANSPLANT MORTALITY IN RECENT YEARS
129. Leukaemia relapse after allogeneic transplants for AML: predictive role of WT1 expression
130. Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative donor: incidence, risk factors and outcome
131. Protein-C serum levels as a prognostic indicator of sepsis and related diseases in allogeneic bone marrow transplantation
132. Haploidentical DLI for relapse post haplo bone marrow transplantation with high- dose of cyclophosphamide post-transplant as GvHD prophylaxis: is it feasible?
133. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
134. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab
135. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
136. A boost of CD34(+)-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation
137. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
138. Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up.
139. Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring.
140. Acute graft versus host disease 1976-2020: reduced incidence and predictive factors.
141. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
142. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
143. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
144. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.
145. Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant.
146. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
147. The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.
148. Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
149. Second haploidentical stem cell transplantation for primary graft failure.
150. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.